The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Jury Out on Immunomodulatory Therapy for Kids with Severe COVID-19

Jury Out on Immunomodulatory Therapy for Kids with Severe COVID-19

September 1, 2020 • By Megan Brooks

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Immunomodulatory therapy is not recommended for most children with COVID-19 who typically will have a mild to moderate course of illness, experts advise in a guidance document in the Journal of the Pediatric Infectious Diseases Society.1

You Might Also Like
  • ACR Releases COVID-19 Clinical Guidance for Pediatric Patients
  • Unprecedented Cluster of Hyperinflammatory Shock in Kids in U.K., possibly Linked to COVID-19
  • U.S. to Tell Doctors to Report Cases of COVID-19 Inflammatory Syndrome in Kids

For children with severe or critical COVID-19, immunomodulatory agents “may be beneficial,” but the risks and benefits vary and the decision to use such agents “should be evaluated on a case-by-case basis with input from appropriate specialty services,” they say.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a joint email to Reuters Health, lead authors Hamid Bassiri, MD, PhD, Children’s Hospital of Philadelphia, and Daniel Dulek, MD, Vanderbilt University Medical Center, Nashville, say, “Fortunately, the large majority of children who are infected by SARS-CoV-2 either remain asymptomatic or develop minimal or mild symptoms of COVID-19. In a very small minority of pediatric patients, infection may result in moderate and even severe symptoms, including the development of acute respiratory distress syndrome [ARDS].”

They note that in adults. progression of illness in severe and critical COVID-19 is accompanied by hyperactivation of certain components of the immune system. As such, a number of immunomodulatory approaches have been trialed in adult COVID-19 patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Unfortunately, there continues to be a relative paucity of such studies in pediatric populations. Nonetheless, our goal was to make general pediatricians and pediatric specialists aware of the current literature and the rationale for use of immunomodulators in severe COVID-19 patients, while awaiting more specific guidance based on well-controlled pediatric clinical trials,” Dr. Bassiri and Dr. Dulek explain.

In the absence of such trials, a multidisciplinary panel of pediatric subspecialty physicians and pharmacists with expertise in infectious diseases, rheumatology, hematology/oncology and critical care developed a series of guidance statements based on best available evidence and expert opinion.

Recognizing that definitive evidence is lacking, consideration of immunomodulatory agents in cases of SARS-CoV-2 infection with clinical and biochemical evidence of cytokine storm should be limited to children with clear evidence of critical COVID-19 disease and risk for multi-organ failure, the panel advises.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

To date, there are no immunomodulators with proven efficacy for the treatment of COVID-19 in children; therefore, the panel can’t recommend one immunomodulatory therapy over another.

There are a number of intriguing “unknowns” regarding SARS-CoV-2 infections children, including the full spectrum of disease presentations induced by SARS-CoV-2, Drs. Bassiri and Dulek tell Reuters Health.

“Although we have all heard of COVID-19, MIS-C, ‘COVID toes’ and other presentations of SARS-COV-2, to date we have not developed a complete mechanistic understanding of why certain individuals develop each of these disease manifestations [or remain asymptomatic]. While there may be virus-specific factors, or differences in the route of exposure or the initial inoculum size, host genetics and epigenetics also likely play important roles in determining the disease presentation and its severity,” they explain.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: Children, COVID-19, Pediatric

You Might Also Like:
  • ACR Releases COVID-19 Clinical Guidance for Pediatric Patients
  • Unprecedented Cluster of Hyperinflammatory Shock in Kids in U.K., possibly Linked to COVID-19
  • U.S. to Tell Doctors to Report Cases of COVID-19 Inflammatory Syndrome in Kids
  • ACR Releases COVID-19 & MIS-C Clinical Guidance for Kids with Rheumatic Disease

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.